Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
10 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 40(4); December 2008
Prev issue Next issue
Original Articles
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Res Treat. 2008;40(4):155-163.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.155
AbstractAbstract PDFPubReaderePub
Purpose

This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).

Materials and Methods

One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.

Results

One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC → RT vs. CCRT vs. IC → CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.

Conclusions

This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.

Citations

Citations to this article as recorded by  
  • Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
    Jun Zhang, Guo-lin Tan, Ming Jiang, Tian-sheng Wang, Guo-hui Liu, Shan-shan Xiong, Xiang Qing
    Cellular Signalling.2023; 101: 110530.     CrossRef
  • SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer
    Tai Qian, Zhiwei Zhou, Qiongxia Zhang, Yu-Light Liou, Honghao Zhou
    Medicine.2023; 102(50): e36583.     CrossRef
  • MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma
    Chien-Han Yuan, Wei-Chi Hsu, A.-Mei Huang, Ben-Chih Yuan, I.-Hung Chen, Chia-An Hsu, Rong-Feng Chen, Yih-Min Chu, Hui-Hui Lin, Hung-Lung Ke
    BMC Molecular and Cell Biology.2022;[Epub]     CrossRef
  • Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma
    Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
    Oral Oncology.2022; 134: 106139.     CrossRef
  • Transcription Factor STAT1 Promotes the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells by Upregulating LINC01160
    Jingang Ai, Guolin Tan, Tiansheng Wang, Wei Li, Ru Gao, Yexun Song, Shanshan Xiong, Xiang Qing
    Future Oncology.2021; 17(1): 57.     CrossRef
  • Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells
    Hao Chen, Min Luo, Xiangping Wang, Ting Liang, Chaoyuan Huang, Changjie Huang, Lining Wei
    Cellular & Molecular Biology Letters.2021;[Epub]     CrossRef
  • DNA methylation biomarkers for nasopharyngeal carcinoma
    Baoai Han, Xiuping Yang, Po Zhang, Ya Zhang, Yaqin Tu, Zuhong He, Yongqin Li, Jie Yuan, Yaodong Dong, Davood K. Hosseini, Tao Zhou, Haiying Sun, Edwin Wang
    PLOS ONE.2020; 15(4): e0230524.     CrossRef
  • Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy
    Yueli Tian, Khamis Hassan Bakari, Shanshan Liao, Xiaotian Xia, Xun Sun, Chunxia Qin, Yongxue Zhang, Xiaoli Lan
    Contrast Media & Molecular Imaging.2018; 2018: 1.     CrossRef
  • MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
    Guanhong Huang, Ming-yu Du, Hongming Zhu, Nan Zhang, Zhi-Wei Lu, Lu-Xi Qian, Wenjun Zhang, Xiaokang Tian, Xia He, Li Yin
    Biomedicine & Pharmacotherapy.2018; 106: 217.     CrossRef
  • Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma
    Mingyu Du, Teng Huang, Jing Wu, Jia-Jia Gu, Nan Zhang, Kai Ding, Lu-Xi Qian, Zhi-Wei Lu, Wen-Jun Zhang, Xiao-Kang Tian, Xia He, Li Yin
    Oncotarget.2018; 9(2): 1843.     CrossRef
  • GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
    Guo-Hui Nie, Liang Luo, Hong-Fang Duan, Xiao-Qing Li, Mei-Jun Yin, Zhao Li, Wei Zhang
    Tumor Biology.2016; 37(4): 4559.     CrossRef
  • The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
    Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Ch
    Cancer Research and Treatment.2016; 48(3): 917.     CrossRef
  • MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells
    Kang Zhu, Ying He, Cui Xia, Jing Yan, Jin Hou, Demin Kong, Yeye Yang, Guoxi Zheng
    Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(3): 145.     CrossRef
  • Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
    Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie
    Tumor Biology.2015; 36(9): 6679.     CrossRef
  • Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
    Seung Hwan Moon, Joon Young Choi, Hwan Joo Lee, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Byung-Tae Kim
    Clinical and Experimental Otorhinolaryngology.2015; 8(2): 142.     CrossRef
  • MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells
    Jing Wu, Li Yin, Ning Jiang, Wen-jie Guo, Jia-jia Gu, Meng Chen, You-you Xia, Jian-zhong Wu, Dan Chen, Jian-feng Wu, De-jun Wang, Dan Zong, Nan Zhang, Kai Ding, Teng Huang, Xia He
    Experimental Cell Research.2015;[Epub]     CrossRef
  • miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4
    Ling‐yan Lv, Yu‐zhi Wang, Qian Zhang, Hong‐rui Zang, Xing‐jie Wang
    Cell Biochemistry and Function.2015; 33(8): 534.     CrossRef
  • Chemotherapy of Head and Neck Cancer
    Chang Ki Yeo
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291.     CrossRef
  • MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
    Xiaoming Qi, Jianqiang Li, Changbo Zhou, Chunlei Lv, Min Tian
    FEBS Letters.2014; 588(20): 3732.     CrossRef
  • IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Nasopharyngeal Cancer: Plan Evaluation and Treatment Outcome
    J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim, J. Y. Lee, S. K. Kim, C. G. Lee
    Japanese Journal of Clinical Oncology.2012; 42(12): 1152.     CrossRef
  • Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
    Senem Demirci, Serra Kamer, Gulsen Kara, Ozgur Yildirim, Mustafa Esassolak
    Acta Oto-Laryngologica.2011; 131(8): 852.     CrossRef
  • miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
    Hongping Xia, Samuel S. Ng, Songshan Jiang, William K.C. Cheung, Johnny Sze, Xiu-Wu Bian, Hsiang-fu Kung, Marie C. Lin
    Biochemical and Biophysical Research Communications.2010; 391(1): 535.     CrossRef
  • 10,440 View
  • 66 Download
  • 22 Crossref
Close layer
Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn
Cancer Res Treat. 2008;40(4):164-171.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.164
AbstractAbstract PDFPubReaderePub
Purpose

Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute.

Materials and Methods

Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children's Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen.

Results

One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and Reese-Ellsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae.

Conclusions

In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.

Citations

Citations to this article as recorded by  
  • The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
    Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
    Cancer Research and Treatment.2023; 55(1): 270.     CrossRef
  • Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors
    Emily S Wong, Richard W Choy, Yuzhou Zhang, Wai Kit Chu, Li Jia Chen, Chi Pui Pang, Jason C Yam
    The Lancet Global Health.2022; 10(3): e380.     CrossRef
  • Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma
    Yoon Sunwoo, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Sang In Khwarg, Jaemoon Koh, Sung-Hye Park, Dong Hyun Jo, Jeong Hun Kim, Jung-Eun Cheon, Hyoung Jin Kang
    Children.2022; 9(12): 1983.     CrossRef
  • Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy
    Won Jong Choi, Dong Hyun Jo, Hyoung Jin Kang, Hee Young Shin, Young Suk Yu, Jeong Hun Kim
    Korean Journal of Ophthalmology.2021; 35(1): 73.     CrossRef
  • Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
    Jassada Buaboonnam, Nattee Narkbunnam, Nassawee Vathana, Chayamon Takpradit, Kamon Phuakpet, Bunchoo Pongtanakul, Sasima Tongsai, La-Ongsri Atchaneeyasakul, Kleebsabai Sanpakit
    Pediatric Hematology and Oncology.2019; 36(2): 73.     CrossRef
  • Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
    Francis L. Munier, Maja Beck-Popovic, Guillermo L. Chantada, David Cobrinik, Tero T. Kivelä, Dietmar Lohmann, Philippe Maeder, Annette C. Moll, Angel Montero Carcaboso, Alexandre Moulin, Paula Schaiquevich, Ciara Bergin, Paul J. Dyson, Susan Houghton, Fra
    Progress in Retinal and Eye Research.2019; 73: 100764.     CrossRef
  • Outcomes of Proton Beam Radiation Therapy for Retinoblastoma With Vitreous Seeds
    Eun Hye Jung, Jeong Hun Kim, Joo Young Kim, Dong Hyun Jo, Young Suk Yu
    Journal of Pediatric Hematology/Oncology.2018; 40(8): 569.     CrossRef
  • Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
    Zeren Shen, Jinjin Shao, Jiabin Dai, Yuchen Lin, Xiaochun Yang, Jian Ma, Qiaojun He, Bo Yang, Ke Yao, Peihua Luo
    Toxicology Reports.2016; 3: 78.     CrossRef
  • Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma
    Seung Min Hahn, Hyo Sun Kim, Dong Joon Kim, Sung Chul Lee, Chuhl Joo Lyu, Jung Woo Han
    Pediatric Hematology and Oncology.2016; 33(1): 74.     CrossRef
  • Diagnosis & Treatment of Retinoblastoma: Current Review
    Heewon Chueh
    Clinical Pediatric Hematology-Oncology.2015; 22(1): 38.     CrossRef
  • High‐dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: Report of five cases
    Désirée Caselli, Angela Tamburini, Agostino La Torre, Liliana Pollazzi, Veronica Tintori, Franco Bambi, Roberto Caputo, Maurizio Aricò
    Pediatric Transplantation.2014; 18(6): 631.     CrossRef
  • Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments
    Carlo Venturi, Sandra Bracco, Alfonso Cerase, Samuele Cioni, Paolo Galluzzi, Paola Gennari, Ignazio M. Vallone, Rebecca Tinturini, Cesare Vittori, Sonia De Francesco, Mauro Caini, Alfonso D’Ambrosio, Paolo Toti, Alessandra Renieri, Theodora Hadjistilianou
    Acta Ophthalmologica.2013; 91(4): 335.     CrossRef
  • Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma
    Aman Khurana, Christina A. Eisenhut, Wenshuai Wan, Katayoon B. Ebrahimi, Chirag Patel, Joan M. O’Brien, Kristen Yeom, Heike E. Daldrup-Link
    European Radiology.2013; 23(5): 1271.     CrossRef
  • Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells
    HYUN BEOM SONG, HYOUNG-OH JUN, JIN HYOUNG KIM, YOUNG SUK YU, KYU-WON KIM, BON HONG MIN, JEONG HUN KIM
    Oncology Reports.2013; 30(6): 2713.     CrossRef
  • Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
    Xin Song, Haibo Wang, Renbing Jia, Biyun Cun, Xiaoping Zhao, Yixiong Zhou, Xiaofang Xu, Guanxiang Qian, Shengfang Ge, Xianqun Fan
    International Journal of Molecular Sciences.2012; 13(9): 10736.     CrossRef
  • Long Term Follow-up Results of External Beam Radiotherapy as Primary Treatment for Retinoblastoma
    Sang Yul Choi, Mi-Sook Kim, SungYul Yoo, ChulKoo Cho, YoungHoon Ji, KumBae Kim, YoungSeok Seo, Kyung Duk Park, JunAh Lee, Tai-Won Lee
    Journal of Korean Medical Science.2010; 25(4): 546.     CrossRef
  • 11,751 View
  • 85 Download
  • 16 Crossref
Close layer
Clinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation
Ji Won Lee, Hyery Kim, Hyoung Jin Kang, Han-Soo Kim, Sung-Hye Park, In-One Kim, Hyo Seop Ahn, Hee Young Shin
Cancer Res Treat. 2008;40(4):172-177.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.172
AbstractAbstract PDFPubReaderePub
Purpose

In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).

Materials and Methods

We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.

Results

The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.

Conclusions

The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.

Citations

Citations to this article as recorded by  
  • High‐dose chemotherapy followed by autologous stem cell transplantation in pediatric patients with relapsed osteosarcoma
    Sung Han Kang, Wanlim Kim, Jong Seok Lee, Jin Kyung Suh, Hyery Kim, Dong Kwan Kim, Se Hoon Choi, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Sung Wook Seo, Ho Joon Im, Ji Won Lee, Kyung‐Nam Koh
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis
    Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Jung-Eun Cheon, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
    Mohammadreza Bordbar, Ali Sarfaraz, Sezaneh Haghpanah, Omidreza Zekavat, Soheila Zareifar, Tahereh Zarei
    Global Pediatric Health.2021;[Epub]     CrossRef
  • 1
    L.V. Hryvkova
    Practical oncology.2021; 4(1): 30.     CrossRef
  • Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma
    Suguru Uemura, Takeshi Mori, Shinya Ishiko, Satoru Takafuji, Nanako Nino, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Hitomi Hara, Teruya Kawamoto, Toshihiro Akisue, Kazumoto Iijima
    Pediatric Hematology and Oncology.2020; 37(4): 337.     CrossRef
  • Pulmonary tuberculosis mimicking radiation pneumonitis in a patient with neck malignancy
    Kyungsoo Bae, Kyung Nyeo Jeon, Hoon Sik Choi, Dae Hyun Song, Ho Cheol Kim
    Medicine.2019; 98(27): e16398.     CrossRef
  • High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
    C R Hong, H J Kang, M S Kim, H Y Ju, J W Lee, H Kim, H-S Kim, S-H Park, K D Park, J D Park, H Y Shin, H S Ahn
    Bone Marrow Transplantation.2015; 50(10): 1375.     CrossRef
  • High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study
    Kjetil Boye, Adalberto Brach Del Prever, Mikael Eriksson, Gunnar Sæter, Amelia Tienghi, Paula Lindholm, Franca Fagioli, Sigmund Skjeldal, Stefano Ferrari, Kirsten Sundby Hall
    Pediatric Blood & Cancer.2014; 61(5): 840.     CrossRef
  • LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy
    XIN HUA LONG, ZHEN HAO ZHONG, AI FEN PENG, LIANG BO ZHU, HENG WANG, GUO MEI ZHANG, ZHI LI LIU
    Molecular Medicine Reports.2014; 10(6): 2967.     CrossRef
  • Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
    Colin Moore, Don Eslin, Alejandro Levy, Jessica Roberson, Vincent Giusti, Robert Sutphin
    Pediatric Blood & Cancer.2010; 55(6): 1096.     CrossRef
  • Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma
    Masanori Kawano, Hideji Nishida, Yasunari Nakamoto, Hiroshi Tsumura, Hiroyuki Tsuchiya
    Clinical Orthopaedics and Related Research®.2010; 468(5): 1373.     CrossRef
  • 10,126 View
  • 67 Download
  • 11 Crossref
Close layer
Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer
Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung
Cancer Res Treat. 2008;40(4):178-183.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.178
AbstractAbstract PDFPubReaderePub
Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by  
  • African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
    Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
    Head & Neck.2022; 44(10): 2069.     CrossRef
  • Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
    Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
    World Journal of Nuclear Medicine.2021; 20(02): 164.     CrossRef
  • Modern Radiology in the Management of Head and Neck Cancer
    G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
    Clinical Oncology.2016; 28(7): 440.     CrossRef
  • Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
    Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
    Journal of Craniofacial Surgery.2011; 22(1): 348.     CrossRef
  • 11,097 View
  • 72 Download
  • 4 Crossref
Close layer
A Matched-cohort Comparison of Laparoscopic Renal Cryoablation using Ultra-thin Cryoprobes with Open Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma
Young Hwii Ko, Hong Seok Park, Du Geon Moon, Jeong Gu Lee, Je Jong Kim, Duck Ki Yoon, Seok Ho Kang, Jun Cheon
Cancer Res Treat. 2008;40(4):184-189.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.184
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the feasibility and efficacy of performing laparoscopic renal cryoablation (LRC) for the treatment of RCC, as compared with open partial nephrectomy (OPN), which is the established NSS.

Materials and Methods

From April 2004, among the patients who underwent LRC with a 1.47 mm cryoprobe, we enrolled 20 patients who were pathologically confirmed as having RCC with a tumor size smaller than 4 cm. These patients were matched with a group of 20 patients, who were selected based on the pre-operative characteristics of the tumor and those of the patients, from a pre-existing database of the patients who underwent OPN during the same period.

Results

The mean age and tumor size were 56.3±11.5 years and 2.4±1.7 cm in the LRC group, and 57.6±10.9 years and 2.2±1.1 cm in the OPN group. The two groups were similar for their age, gender, BMI, ASA, the tumor characteristics and the indications for operation. While the pathologic results and the operation time showed similarity, the EBL (98±87 ml vs 351±147 ml, respectively, p=0.001), the transfusion rate (10% vs 40%, respectively, p=0.03) and the hospital stay (4.2±1.5 days vs 8.2±2.4 days, respectively, p=0.005) were significantly less in the LRC group. Major complications did not occur in the LRC group, but in the OPN group, one patient experienced urine leakage and one patient had a perirenal hematoma. During the mean follow up of 27.3±10.8 months and 28.7±14.9 months for each group, respectively, all the patients remained disease-free with no evidence of local recurrence or metastases.

Conclusions

LRC using ultra-thin cryoprobes for the treatment of small RCC showed similar effective oncologic results with the merits of minimal invasiveness, as compared with OPN, during the intermediate term follow up.

Citations

Citations to this article as recorded by  
  • Stage IA papillary and chromophobe renal cell carcinoma: effectiveness of cryoablation and partial nephrectomy
    Annemarie Uhlig, Johannes Uhlig, Brian Shuch, Hyun S. Kim
    Insights into Imaging.2024;[Epub]     CrossRef
  • Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis
    Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, Reza Sari Motlagh, Hadi Mostafaei, Fahad Quhal, Ekaterina Laukhtina, Pawel Rajwa, Abdulmajeed Aydh, Frederik König, Maximilian Pallauf, Benjamin Pradere, Jun Miki, Takahiro Kimura, Shin Egawa, Shahrokh
    Urologic Oncology: Seminars and Original Investigations.2022; 40(7): 315.     CrossRef
  • Partial nephrectomy vs cryoablation for T1a renal cell carcinoma: A comparison of survival benefit stratified by tumour size
    Xinyang Liao, Shi Qiu, Wanyu Wang, Xiaonan Zheng, Kun Jin, Shiyu Zhang, Yige Bao, Lu Yang, Qiang Wei
    Cancer Epidemiology.2019; 59: 221.     CrossRef
  • Partial nephrectomy versus ablative therapies for cT1a renal masses: A Systematic Review and meta-analysis
    Xu Hu, Yan-Xiang Shao, Yan Wang, Zhi-Qiang Yang, Wei-Xiao Yang, Xiang Li
    European Journal of Surgical Oncology.2019; 45(9): 1527.     CrossRef
  • Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2–4 cm
    Shuai Yan, Wei Yang, Cheng-mei Zhu, Pei-meng Yan, Zhi-chao Wang
    Medicine.2019; 98(21): e15610.     CrossRef
  • Ablative Therapy for Small Renal Masses
    Benjamin L. Taylor, S. William Stavropoulos, Thomas J. Guzzo
    Urologic Clinics of North America.2017; 44(2): 223.     CrossRef
  • A national study of kidney graft tumor treatments: Toward ablative therapy
    Kerem Guleryuz, Arnaud Doerfler, Ricardo Codas, Grégoire Coffin, Jacques Hubert, Eric Lechevallier, Xavier Tillou, L. Badet, B. Barrou, T. Bessede, P. Blanchet, J.M. Boutin, J. Branchereau, T. Culty, V. Delaporte, F. Gaudez, M. Gigante, G. Karam, F. Klein
    Surgery.2016; 160(1): 237.     CrossRef
  • Guía de manejo del carcinoma de células renales
    William Quiroga Matamoros, Fernando Fernandez, Danilo Citarella Otero, Jaime Rangel, Andrea Estrada Guerrero, Iván Darío Patiño
    Urología Colombiana.2016; 25(2): 169.     CrossRef
  • Current Status of Cryotherapy for Prostate and Kidney Cancer
    Seok Cho, Seok Ho Kang
    Korean Journal of Urology.2014; 55(12): 780.     CrossRef
  • Retrospective Comparison of Laparoscopic Partial Nephrectomy Versus Laparoscopic Renal Cryoablation for Small (<3.5 cm) Cortical Renal Masses
    Georgios Haramis, Joseph A. Graversen, Adam C. Mues, Ruslan Korets, Juan Carlos Rosales, Zhamshid Okhunov, Ketan K. Badani, Mantu Gupta, Jaime Landman
    Journal of Laparoendoscopic & Advanced Surgical Techniques.2012; 22(2): 152.     CrossRef
  • Systematic Review of Perioperative and Quality-of-life Outcomes Following Surgical Management of Localised Renal Cancer
    Steven MacLennan, Mari Imamura, Marie C. Lapitan, Muhammad Imran Omar, Thomas B.L. Lam, Ana M. Hilvano-Cabungcal, Pam Royle, Fiona Stewart, Graeme MacLennan, Sara J. MacLennan, Philipp Dahm, Steven E. Canfield, Sam McClinton, T.R. Leyshon Griffiths, Börje
    European Urology.2012; 62(6): 1097.     CrossRef
  • Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
    Steven MacLennan, Mari Imamura, Marie C. Lapitan, Muhammad Imran Omar, Thomas B.L. Lam, Ana M. Hilvano-Cabungcal, Pam Royle, Fiona Stewart, Graeme MacLennan, Sara J. MacLennan, Steven E. Canfield, Sam McClinton, T.R. Leyshon Griffiths, Börje Ljungberg, Ja
    European Urology.2012; 61(5): 972.     CrossRef
  • Perioperative, Oncologic, and Functional Outcomes of Laparoscopic Renal Cryoablation and Open Partial Nephrectomy: A Matched Pair Analysis
    Tobias Klatte, Julian Mauermann, Gertraud Heinz-Peer, Matthias Waldert, Peter Weibl, Hans Christoph Klingler, Mesut Remzi
    Journal of Endourology.2011; 25(6): 991.     CrossRef
  • 9,302 View
  • 81 Download
  • 13 Crossref
Close layer
Association of Single Nucleotide Polymorphisms in PIM-1 Gene with the Risk of Korean Lung Cancer
Dae Sik Kim, Jae Sook Sung, Eun Soon Shin, Jeong-Seon Ryu, In Keun Choi, Kyong Hwa Park, Yong Park, Eui Bae Kim, Seh Jong Park, Yeul Hong Kim
Cancer Res Treat. 2008;40(4):190-196.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.190
AbstractAbstract PDFPubReaderePub
Purpose

The expression of the PIM-1 gene, which is a proto-oncogene that encodes a serine/threonine kinase, is associated with multiple cellular functions such as proliferation, differentiation, apoptosis and tumorigenesis. In particular, several studies have reported that the PIM-1 gene is associated with the development of lymphoma, leukemia and prostate cancer. Therefore, this study was conducted to evaluate the association between the single nucleotide polymorphisms in the PIM-1 gene and the risk of lung cancer occurrence in the Korean population.

Materials and Methods

To evaluate the role of the PIM-1 gene in the development of lung cancer, the genotypes of the PIM-1 gene were determined in 408 lung cancer patients and 410 normal subjects.

Results

We found that the T-C-T-C haplotypes of the PIM-1 gene (-1196 T>C, IVS4 +55 T>C, IVS4 +1416 T>A and +3684 C>A) were associated with an increased risk of lung cancer [adjusted odds ratio (aOR): 3.98; 95% CI: 1.24~12.75, p-value: 0.020]. In particular, these haplotypes showed an increased risk of lung cancer in males (aOR: 5.67; 95% CI: 1.32~24.30, p-value: 0.019) and smokers (aOR: 7.82; 95% CI: 1.75~34.98, p-value: 0.007).

Conclusions

The present results suggest that the T-C-T-C haplotype of the PIM-1 gene could influence the risk of developing smoking-related lung cancer in the Korean population. Additional functional studies with an larger sample sized analysis are warranted to reconfirm our findings.

Citations

Citations to this article as recorded by  
  • A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target
    Ajaya Kumar Rout, Budheswar Dehury, Satya Narayan Parida, Sushree Swati Rout, Rajkumar Jena, Neha Kaushik, Nagendra Kumar Kaushik, Sukanta Kumar Pradhan, Chita Ranjan Sahoo, Ashok Kumar Singh, Meenakshi Arya, Bijay Kumar Behera
    International Journal of Biological Macromolecules.2024; 270: 132030.     CrossRef
  • Impact of Pim1 mutations on the survival outcomes of patients with breast cancer: Insights from a clinical study
    Syed Sultan Beevi, Kavitha Anbrasu, Vinod Kumar Verma, Nagesh Kishan Panchal, Krishna Kiran Kannepalli, Raghu Ram Pillarisetti, Sailaja Madigubba, Jyotsana Dwivedi, Neha Damodar, Radhika Chowdary Darapuneni
    Human Gene.2024; 40: 201295.     CrossRef
  • HCG11 inhibits salivary adenoid cystic carcinoma by upregulating EphA2 via binding to miR-1297
    Shujuan Yan, Meng Wang
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(2): 257.     CrossRef
  • Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
    Aanchal Rathi, Dhiraj Kumar, Gulam Mustafa Hasan, Mohammad Mahfuzul Haque, Md Imtaiyaz Hassan
    Biochimica et Biophysica Acta (BBA) - General Subjects.2021; 1865(11): 129995.     CrossRef
  • Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)
    Jiajie Xu, Xin Zhu, Qingling Li, Chao Chen, Zhenying Guo, Zhuo Tan, Chuanming Zheng, Minghua Ge
    Cancer Cell International.2018;[Epub]     CrossRef
  • PIM Kinase as an Executional Target in Cancer
    Xinning Zhang, Mengqiu Song, Joydeb Kumar Kundu, Mee-Hyun Lee, Zhen-Zhen Liu
    Journal of Cancer Prevention.2018; 23(3): 109.     CrossRef
  • HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372
    Jiahui An, Jie Xu, Jiao Li, Song Jia, Xiaonan Li, Yanan Lu, Yuxin Yang, Zhuojia Lin, Xiaoru Xin, Mengying Wu, Qidi Zheng, Hu Pu, Xin Gui, Tianming Li, Dongdong Lu
    Oncotarget.2017; 8(30): 49093.     CrossRef
  • Expressions of osteopontin (OPN), ανβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC)
    Yi Jin, Da-yue Tong, Lu-ying Tang, Jian-ning Chen, Jing Zhou, Zhi-ying Feng, Chun-kui Shao
    Chinese Journal of Cancer Research.2012; 24(2): 103.     CrossRef
  • Overexpression of Osteopontin, αvβ3 and Pim-1 Associated with Prognostically Important Clinicopathologic Variables in Non-Small Cell Lung Cancer
    Yi Jin, Da-yue Tong, Jian-ning Chen, Zhi-ying Feng, Jian-yong Yang, Chun-kui Shao, Jia-ping Li, Rossella Rota
    PLoS ONE.2012; 7(10): e48575.     CrossRef
  • No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population
    Jae-Sook Sung, Kyong-Hwa Park, Seung-Tae Kim, Jae-Hong Seo, Sang-Won Shin, Jun-Suk Kim, Yeul-Hong Kim
    Genomics & Informatics.2010; 8(4): 194.     CrossRef
  • 11,300 View
  • 85 Download
  • 10 Crossref
Close layer
Altered Expression of Smad Proteins in T or NK-cell Lymphomas
Jai Hyang Go
Cancer Res Treat. 2008;40(4):197-201.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.197
AbstractAbstract PDFPubReaderePub
Purpose

Smad proteins mediate cellular signaling through the transforming growth factor-β family (TGF-βs). Smads 2 and 3 transmit signals from TGF-β, and Smad4 is a common mediator, as well. However, little is known concerning the expression patterns of Smads in lymphoid tissue.

Materials and Methods

Immunohistochemistry for Smad3 and Smad4 was performed on paraffin-embedded tissue sections collected from 26 T- or NK-cell lymphomas.

Results

Nearly all cells in germinal centers were positive for Smad3, and more than 50% of paracortical cells were positive for Smad3 in reactive lymphoid tissue. When Smad4 immunostaining was conducted, nearly all the cells in the germinal centers showed diffuse cytoplasmic staining, and most of them exhibited nuclear positivity, as well. In addition, more than 50% of the cells in the paracortex were positive for Smad4. Furthermore, the Smad3 staining pattern was preserved in all malignant lymphomas, but four of these cases (15%) exhibited decreased expression of Smad4. All lymphoblastic lymphomas showed strong positivity in most of tumor cells, but one unspecified peripheral lymphoma, two nasal NK/T cell lymphomas, and one anaplastic large cell lymphoma were negative for Smad4.

Conclusions

These results suggest that TGF-β-specific Smads may be actively involved in signal transduction in lymphoid organs and that Smad-mediated TGF-β signaling pathways are operative in malignant lymphoma. In addition, loss of Smad4 expression might be associated with development of some T-cell lymphomas.

Citations

Citations to this article as recorded by  
  • Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review
    Karen E. Wain, Marissa S. Ellingson, Jamie McDonald, Amanda Gammon, Maegan Roberts, Pavel Pichurin, Ingrid Winship, Douglas L. Riegert-Johnson, Jeffrey N. Weitzel, Noralane M. Lindor
    Genetics in Medicine.2014; 16(8): 588.     CrossRef
  • Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma
    Chang Ohk Sung, Sang Cheol Kim, Sivasundaram Karnan, Kennosuke Karube, Hyung Jin Shin, Do-Hyun Nam, Yeon-Lim Suh, Seok-Hyung Kim, Ji Yeon Kim, Seok Jin Kim, Won Seog Kim, Masao Seto, Young-Hyeh Ko
    Blood.2011; 117(4): 1291.     CrossRef
  • 7,751 View
  • 42 Download
  • 2 Crossref
Close layer
Case Reports
A Case of Medullary Thyroid Carcinoma in which the Skin Metastasis was Concurrently Present and Response Occurred to Chemotherapy
Won Je Choi, Yun Young Lee, Soyon Kim, Yun Kwon Kim, Eun Sil Kim, Seung O Seo, Jae Hyun Jo, Seung Min Lee, Hyo Jin Lee
Cancer Res Treat. 2008;40(4):202-206.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.202
AbstractAbstract PDFPubReaderePub

Medullary thyroid carcinoma accounts for 3% of all thyroid gland malignancies. It commonly metastasizes to liver, lung, and bone. It rarely metastasizes to skin, and only a few such cases have been documented. Cutaneous metastasis suggests a poor prognosis, with a mean survival of 7.5-19 months. The most effective treatment for skin metastasis is complete surgical removal of all local and regional lesions. The response to systemic chemotherapy is typically poor. We report a case of medullary thyroid carcinoma with cutaneous metastases, which responded to chemotherapy.

Citations

Citations to this article as recorded by  
  • Thyroid Cancer With Cutaneous Metastases
    Bao Y. Sciscent, Hanel W. Eberly, Neerav Goyal, David Goldenberg
    Ear, Nose & Throat Journal.2024;[Epub]     CrossRef
  • Cutaneous Metastasis of Medullary Carcinoma Thyroid Masquerading as Subcutaneous Nodules Anterior Chest and Mandibular Region
    Rahul Mannan, Jasmine Kaur, Jasleen Kaur, Sanjay Piplani, Harjot Kaur, Harleen Kaur
    Case Reports in Dermatological Medicine.2014; 2014: 1.     CrossRef
  • Cutaneous Metastasis of Medullary Thyroid Carcinoma as the Initial Manifestation of an Otherwise Limited Malignancy: A Case Report
    Sanaz Sanii, Seyed Mohammad Tavangar
    The American Journal of Dermatopathology.2011; 33(7): 716.     CrossRef
  • 9,205 View
  • 67 Download
  • 3 Crossref
Close layer
Breast Cancer Metastasis to the Stomach Resembling Early Gastric Cancer
Wan Kyu Eo
Cancer Res Treat. 2008;40(4):207-210.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.207
AbstractAbstract PDFPubReaderePub

Breast cancer metastases to the stomach are infrequent, with an estimated incidence rate of approximately 0.3%. Gastric metastases usually are derived from lobular rather than from ductal breast cancer. The most frequent type of a breast cancer metastasis as seen on endoscopy to the stomach is linitis plastica; features of a metastatic lesion that resemble early gastric cancer (EGC) are extremely rare. In this report, we present a case of a breast cancer metastasis to the stomach from an infiltrating ductal carcinoma (IDC) of the breast in a 48-year-old woman. The patient had undergone a left modified radical mastectomy with axillary dissection nine years prior. A gastric endoscopy performed for evaluation of nausea and anorexia showed the presence of a slightly elevated mucosal lesion in the cardia, suggestive of a type IIa EGC. A histological examination revealed nests of a carcinoma in the subepithelial lymphatics, and immunohistochemical staining for estrogen receptor was positive. This is an extremely rare case with features of type IIa EGC, but the lesion was finally identified as a cancer metastasis to the cardia of the stomach from an IDC of the breast.

Citations

Citations to this article as recorded by  
  • Radiologic patterns of distant organ metastasis in advanced breast cancer patients: Prospective review of computed tomography images
    Bashiru Babatunde Jimah, Emmanuella Amoako, Emmanuel Owusu Ofori, Patrick Kafui Akakpo, Luke Adagrah Aniakwo, Kofi Ulzen‐Appiah, Emmanuel Gustav Imbeah, Martin Tangnaa Morna, Patience Koggoh, Harry Akligoh, Randy Tackie, Aida Manu, Lily Paemka, Benjamin D
    Cancer Reports.2024;[Epub]     CrossRef
  • Case report: Cutaneous metastases as a first manifestation from breast cancer with concurrent gastric metastases
    Lulu Xu, Congcong Wang, Xiaoling Yang, Liangliang Dong
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Breast cancer metastasis to the stomach mimicking early gastric cancer
    Kosuke Tanaka, Yohei Yabuuchi, Daisuke Yamashita, Tetsuro Inokuma
    JGH Open.2023; 7(9): 667.     CrossRef
  • De novo gastric metastasis from invasive lobular carcinoma of the breast: report of three cases and literature review
    Jessica Gonzalez Suerdieck, Juliana Alves Souza, Mateus Mattioni, Almir Galvão Vieira Bitencourt
    Mastology.2022;[Epub]     CrossRef
  • S1847 Breast Cancer Metastases to the Gastrointestinal Tract: A Case Report
    Vimal Bodiwala, Akhtar Cheema, Elliot Bigajer
    American Journal of Gastroenterology.2021; 116(1): S813.     CrossRef
  • Breast cancer metastasizing to the stomach mimicking primary gastric cancer: A case report
    Kwangil Yim, Sang Mi Ro, Jieun Lee
    World Journal of Gastroenterology.2017; 23(12): 2251.     CrossRef
  • Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastases
    Ali El-Hage, Carolanne Ruel, Wahiba Afif, Hussein Wissanji, Jean-Charles Hogue, Christine Desbiens, Guy Leblanc, Éric Poirier
    Journal of Surgical Oncology.2016; 114(5): 543.     CrossRef
  • Breast Cancer Metastasis to the Stomach That Was Diagnosed after Endoscopic Submucosal Dissection
    Masahide Kita, Masashi Furukawa, Masaya Iwamuro, Keisuke Hori, Yoshiro Kawahara, Naruto Taira, Tomohiro Nogami, Tadahiko Shien, Takehiro Tanaka, Hiroyoshi Doihara, Hiroyuki Okada
    Case Reports in Gastrointestinal Medicine.2016; 2016: 1.     CrossRef
  • BREAST CANCER METASTASIS IN THE STOMACH: WHEN THE GASTRECTOMY IS INDICATED ?
    Marcus Vinicius Rozo RODRIGUES, Valdir TERCIOTI-JUNIOR, Luiz Roberto LOPES, João de Souza COELHO-NETO, Nelson Adami ANDREOLLO
    ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2016; 29(2): 86.     CrossRef
  • Synchronous Primary Carcinoma of Breast and Ovary Versus Ovarian Metastases
    Budhi S. Yadav, S.C. Sharma, Tyler P. Robin, Sharon Sams, Anothony D. Elias, Virginia Kaklamani, P. Kelly Marcom, Sara Schaefer, Gloria J. Morris
    Seminars in Oncology.2015; 42(2): e13.     CrossRef
  • Clinicopathological features of gastric metastasis from breast cancer in three cases
    Kenta Koike, Kenji Kitahara, Mayumi Higaki, Masako Urata, Fumio Yamazaki, Hirokazu Noshiro
    Breast Cancer.2014; 21(5): 629.     CrossRef
  • 8,903 View
  • 142 Download
  • 11 Crossref
Close layer
TTP-HUS Associated with Sunitinib
Moon Ki Choi, Jung Yong Hong, Jun Ho Jang, Ho Yeong Lim
Cancer Res Treat. 2008;40(4):211-213.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.211
AbstractAbstract PDFPubReaderePub

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Adverse reactions to drugs increasingly are reported as probable causes of TTP-HUS. Many chemotherapeutic agents have also been implicated in causing TTP-HUS. We reported a woman with metastatic renal cell carcinoma who presented with TTP-HUS associated with sunitinib. She had gross hematuria and generalized edema. The hemoglobin concentration was 8.9 g/dl and the platelet count was 46,000/mm3. Her reticulocyte count was increased to 4.1% and the peripheral blood smear revealed red blood cell fragmentation and spherocytes. The patient completely recovered after discontinuing the use of sunitinib and undergoing plasmapheresis. Because of the increasing use of sunitinib in the treatment of cancer patients, oncologists should be aware of the possibility of TTP-HUS related to sunitinib, as early recognition and prompt therapeutic intervention can be beneficial.

Citations

Citations to this article as recorded by  
  • Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy
    Anukul Ghimire, Rebecca Brassington, Kim Solez, Aminu Bello
    BMJ Case Reports.2024; 17(1): e255841.     CrossRef
  • Nonthrombocytopenic, noninflammatory simplex purpura during sunitinib therapy
    Marta García‐Legaz Martínez, Álvaro Martínez‐Doménech, Gemma Pérez‐Pastor, Jorge Magdaleno‐Tapial, Cristian Valenzuela‐Oñate, Víctor Alegre‐de Miquel, Amparo Pérez‐Ferriols
    International Journal of Dermatology.2019;[Epub]     CrossRef
  • Thrombotic microangiopathy in cancer patients
    Alexander D. Makatsariya, Ismail Elalamy, Alexander V. Vorobev, Angelina S. Bakhtina, Muyang Meng, Victoria O. Bitsadze, Jamilya Kh. Khizroeva
    Annals of the Russian academy of medical sciences.2019; 74(5): 323.     CrossRef
  • Thrombotic microangiopathy in cancer
    Ilene Ceil Weitz
    Thrombosis Research.2018; 164: S103.     CrossRef
  • Cancer drugs and the glomerulus
    Hitesh H Shah, Nupur N Uppal, Mark A Perazella
    Journal of Onco-Nephrology.2018; 2(2-3): 78.     CrossRef
  • Therapeutic Plasma Exchange and Its Impact on Drug Levels
    Caleb W Cheng, Jeanne E Hendrickson, Christopher A Tormey, Davinder Sidhu
    American Journal of Clinical Pathology.2017; 148(3): 190.     CrossRef
  • Thrombotic Microangiopathy, Cancer, and Cancer Drugs
    Hassan Izzedine, Mark A. Perazella
    American Journal of Kidney Diseases.2015; 66(5): 857.     CrossRef
  • Sunitinib-associated Thrombotic Microangiopathy: A Significant Risk
    F.D. Buckley, G. Preston, D.J. Meiklejohn, D. Adamson
    Clinical Oncology.2014; 26(8): 515.     CrossRef
  • Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature
    Rebecca L. Ruebner, Lawrence Copelovitch, Nicholas F. Evageliou, Michelle R. Denburg, Jean B. Belasco, Bernard S. Kaplan
    Pediatric Nephrology.2014; 29(5): 863.     CrossRef
  • Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
    Liliane Hobeika, Sally E Self, Juan Carlos Q Velez
    BMC Nephrology.2014;[Epub]     CrossRef
  • Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature
    Imane El Dika, Deborah Mukherji, Sally Temraz, Rita Assi, Ali Shamseddine
    Case Reports in Medicine.2014; 2014: 1.     CrossRef
  • Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor
    Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Nilgün Kaya
    Journal of Oncology Pharmacy Practice.2014; 20(4): 298.     CrossRef
  • A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura
    Eun Jin Kim, Yun Mi Choi, Sin Won Lee, Yeon Jung Ha, Jae Lyun Lee
    Korean Journal of Medicine.2013; 84(2): 303.     CrossRef
  • Thrombotic Microangiopathy Associated with Bortezomib Treatment in a Patient with Relapsed Multiple Myeloma
    Urpu Salmenniemi, Kari Remes
    Hematology Reports.2012; 4(2): e13.     CrossRef
  • Hematologic toxicities of small molecule tyrosine kinase inhibitors
    Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari
    Targeted Oncology.2011; 6(4): 203.     CrossRef
  • Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
    H. Izzedine, C. Massard, J. C. Soria
    Clinical Kidney Journal.2011; 4(1): 78.     CrossRef
  • Docetaxel-Induced Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome–Related Complex in a Patient With Metastatic Prostate Cancer?
    Anuj Shrestha, Pam Khosla, Yunfei Wei
    American Journal of Therapeutics.2011; 18(5): e167.     CrossRef
  • Micafungin-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Review of the Literature
    Maisa Nazzal, Fadi Safi, Freda Arma, Mustafa Nazzal, Mahvish Muzaffar, Ragheb Assaly
    American Journal of Therapeutics.2011; 18(6): e258.     CrossRef
  • Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
    Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2009; 41(2): 67.     CrossRef
  • 10,438 View
  • 65 Download
  • 19 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP